B1344 / Tasly - LARVOL DELTA

a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD） (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Tasly Biopharmaceuticals Co., Ltd.

New P1 trial • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

B1344 ameliorates non-alcoholic steatohepatitis in HFCD-HF/G-induced mice: exploring the therapeutic efficacy and mechanism of a novel FGF21 analog. (PubMed, Eur J Pharmacol) - "B1344 is a modified PEGylated FGF21 analog with enhanced stability and bioactivity. The multi-target modulation in liver and AT including FGF21 resistance was involved in its underlying mechanisms. This study not only provides support for further clinical trials of B1344, but also benefits deeper understanding of FGF21 function."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Inflammation • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • FGF21

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Tasly Biopharmaceuticals Co., Ltd.

New P1 trial • Hepatology • Non-alcoholic Steatohepatitis